Equities

Valiant Laboratories Ltd

VALIANTLAB:NSI

Valiant Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)142.20
  • Today's Change-2.95 / -2.03%
  • Shares traded204.34k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Valiant Laboratories Limited is an India-based active pharmaceutical ingredient (API)manufacturing company. The Company is engaged in manufacturing and dealing in specialty chemicals and pharma intermediates in India and abroad. The Company is focused on manufacturing paracetamol API/bulk drug, which has various applications like uses in treatment of conditions, such as headache, muscle ache, arthritis, back ache, toothache, cold and fever. It operates in a single location manufacturing facility at Tarapur industrial estate. Its manufacturing facility is located at a distance of approximately 150 kilometers (km) from Nhava Sheva Port (JNPT). The Company’s subsidiary is VALIANT ADVANCED SCIENCES PRIVATE LIMITED.

  • Revenue in INR (TTM)--
  • Net income in INR--
  • Incorporated2021
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Wanbury Ltd5.69bn233.39m4.91bn1.58k21.07--13.580.86297.127.12173.80--------3,598,099.00--6.56----46.1543.924.104.54--1.82-----2.265.95-112.76--34.73--
Kilitch Drugs (India) Ltd1.55bn145.71m5.52bn153.0037.24--34.213.569.219.2198.24--------10,132,730.00--2.63--3.5939.6833.858.255.01--3.43--2.9322.2022.3041.8215.191.79--
ZIM Laboratories Ltd3.67bn172.46m5.53bn525.0032.082.3216.651.503.543.5475.3449.000.93212.543.76--4.383.886.666.5453.3448.304.693.970.91823.670.3131---7.801.84-29.422.3729.41--
Valiant Laboratories Ltd-100.00bn-100.00bn6.18bn--------------------------------------------------60.35--27.66------
IND Swift Laboratories Ltd12.81bn3.07bn6.60bn1.50k2.150.70891.830.515551.9951.99216.90157.640.8573.453.80--20.585.0025.676.1339.4742.8224.028.522.941.700.0175--6.1011.10784.4470.8223.60--
Medicamen Biotech Ltd1.71bn126.93m6.63bn388.0053.35--36.533.899.789.78131.89--------4,398,250.00--7.17--10.4446.8833.856.5810.87--4.76--8.6122.024.77-0.35557.98-4.210.00
Albert David Ltd3.62bn754.20m6.68bn1.27k8.861.748.121.84132.16132.16635.16671.050.78682.6712.15--16.3710.0020.8513.1565.3061.0320.8111.873.31124.700.008612.896.122.72108.4933.5940.8713.90
Sakar Healthcare Ltd1.51bn124.73m7.50bn297.0056.55--25.694.976.106.1073.58--------5,082,286.00--6.35--7.5946.1844.288.2610.84--2.40----4.0020.23-16.3027.3156.31--
Nectar Lifesciences Ltd16.86bn49.95m7.67bn1.59k148.700.717311.670.4550.230.2379.1647.680.76971.745.12--0.228-0.29560.3969-0.54128.6818.390.2963-0.40520.59071.060.3728--10.63-9.54120.65-36.29-5.06--
Data as of May 17 2024. Currency figures normalised to Valiant Laboratories Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.